(Not applicable.)
1. Field of the Invention
The present invention relates to an apparatus and method for applying component parts of a sealant which when mixed transforms from a fluidic state to a non-fluidic state. In particular but not exclusively, the present invention is directed to an apparatus and process in which sealant components are mixed prior to being applied to biological tissue to effect hemostasis or achieve other therapeutic results.
2. Description of Related Art Including Information Disclosed under 37 CFR 1.97 and 37 CFR 1.98
Use of tissue sealants and other biological materials is an important emerging surgical technique, well adapted for the operating room or field environments such as the doctor's office or mobile medical units. In addition, the application of such sealants via a catheter provides a non evasive medical technique. Preferred sealants include fibrin sealants which are formed from blood plasma components and comprise, on the one hand, a first component containing fibrinogen and Factor XIII and on the other hand a second component which usually includes thrombin, and calcium ions.
The fibrinogen is capable of a polymerizing and being cross-linked to form a solid fibrin clot when the components are mixed. The necessary additional factors to simulate relevant portions of the natural blood coagulation cascade are suitably distributed between the fibrinogen and thrombin components.
High levels of protection against transmission of infections or induction of immunological reactions can be assured by using an autologous or single-donor source for both components. Such sealants are highly effective, are biologically degraded without residue and may promote wound healing.
Depending upon the potency of the particular formulations employed, coagulation of the sealant may take place very rapidly, yielding a gel within perhaps 10 or 20 seconds after mixing of the two components. Though often very desirable for surgical reasons, such fast-acting properties present potential problems of fouling or clogging. These problems must be overcome in devising suitable applicators, and methods of application.
A popular manually operable applicator for such two-component sealants employs a dual syringe construction wherein two syringes, connected by a yoke, each provide a reservoir for one of the components. In most prior devices, the sealant components are discharged in separate streams and mixed externally of the applicator. Such applicators are similar in principle to household epoxy glue applicators commonly available in hardware stores. Achieving effective mixing externally of the applicator is problematic.
In U.S. Pat. No. 5, 266,877, and the above applications, the present inventor teaches various constructions of a dual syringe applicator wherein the fluid sealant components are mixed internally.
Antanavich et al. U.S. Pat. No. 5,585,007, whose disclosure and references are hereby incorporated herein by reference thereto, provides an extensive discussion of the literature relating to fibrinogen sealant preparation (column 1, line 20 to column 4, line 62) and applicators column 4 line 62 to column 5, line 14), as well as a bibliography, (columns 6-10) and is a helpful guide to the teachings of prior workers in the field.
In one or more of the above copending applications the possibility of retrograde clearing of the mixed fluids pathway within the applicator, using suction, is also disclosed. The applicator is provided with suitable suction conduits and valving to apply suction to the work surface, to prepare it for the application of sealant, for example by removing fluids. As taught, the valving is operable to effect retrograde clearing of a sealant dispensing pathway. Enhanced mixing is possible for example, by impingement and problems of fouling by deposited solids are avoided.
Such applicators, and methods, are remarkably effective for applying sealants to exposed biological surfaces. However, it would be desirable to provide a surgeon, or other user, with additional choices, for example, an applicator and method that could effectively apply sealant to internal biological locations.
One difficulty is that the coagulating nature of the sealants causes the discharge opening or openings of an application device to become clogged so that flow out of the applicator slows down or stops.
While the above-referenced copending applications disclose effective clearing-enabled sealant application devices and methods, their techniques are generally intended for application of sealant to exposed and accessible work surfaces.
There is accordingly a need for a sealant applicator and method that can be used to reach an unexposed or inaccessible location.
The present invention solves this problem by providing a sealant applicator comprising a dual catheter communicating with fluid sealant agent sources, for example, two internal reservoirs, which sealant applicator can effectively deliver multiple sealant components to a remote tip of the catheter for mixing and dispensing to an area of application. Preferably this catheter is a dual catheter having one catheter movably mounted with respect to another, for example longitudinally within the other. The movable catheter is then used as a plunger to unclog the openings.
The present invention enables an effective sealant composition to reach an area of application by mixing the sealant components to application or contact with the work surface and providing for removal of coagulated sealant.
Preferably, although not necessarily, the sealant is a biological sealant, for example a tissue adhesive, and the area of application is a biological tissue subject to surgery. The sealant components can comprise a first, structural component capable of gelling, and preferably of solidification and a second, activation component which activates such gelling and, optionally, solidification. More preferably, the sealant is a tissue sealant and the first component comprises fibrinogen and the second component comprises, or can generate a fibrinogen activator, especially thrombin or an equivalent thereof.
The invention also provides a novel surgical method of applying sealant to unexposed or internal biological surfaces, e.g. human or animal anatomical surfaces, that are accessible to a catheter. The use of a dual catheter, which receives a flow of multiple sealant components and mixes the sealant components at the distal end of the catheter, allows the distal end of the catheter to apply a mixed sealant a work site.
One way of carrying out the invention is described in detail below with reference to the drawings which illustrate one or more specific embodiments of the invention and in which:
a is a view similar to
b is a cross sectional view along the lines 3b—3b of
c is a cross sectional view of an alternative embodiment of the present invention;
a are a cross sectional view illustrating an alternative embodiment of the present invention;
a are a cross sectional view illustrating an alternative embodiment of the present invention;
Referring now to
Inner catheter 14 defines an area 16 and is of a smaller diameter than outer catheter 12, this allows outer catheter 12 to surround inner catheter 14 leaving a second area 18.
Outer catheter 12 is configured to have an opening 20 for dispersing a mixed sealant 22.
Sealant 22 is typically comprised of a first sealant agent or component 24 and a second agent or component 26. Component 24 is contained within area 16 and component 26 is contained with area 18. Inner catheter 14 has an opening 28 for discharge of component 24, and in the position shown in
In the preferred embodiment areas 16 and 18 and their respective ratios are of such a configuration as to provide desired proportions of components 24 and 26 to provide a sealant 22 in accordance with the required parameters. As may be desired, areas 16 and 18 and their corresponding volumes may be varied to provide a sealant 22 of various characteristics. For instance, a sealant that may require a longer time to cure or a sealant that may require lesser time to cure by using a lesser or greater proportion or concentration of activator, e.g. thrombin for a fibrinogen sealant.
Areas 16 and 18 are of sufficient size to allow for unimpeded flow of the sealant components.
Inner catheter 14 is slidably or otherwise movably mounted with respect to outer catheter 12 to permit relative movement of inner catheter 14 in the directions of arrow 30.
The movement of outer catheter 12 allows opening 28 of inner catheter 14 to be positioned within outer catheter 12 and away from opening 20. This position allows components 24 and 26 to mix in an area in close proximity to opening 20. Moreover, and as illustrated in
Alternatively, opening 28 may be positioned closer to opening 20, if desired, to reduce the volume of mixing volume 29 and the time components 24 and 26 are in contact with each other inside applicator 10. This may be appropriate for a very fast setting sealant.
To stabilize inner catheter 14 and maintain the appropriate mixing volumes of components 24 and 26, a stabilizing ring 27 (as illustrated by the dashed lines in
Alternatively, and depending on the length of catheters 12 and 14, a plurality of stabilizing rings 27 may positioned within applicator 10 to provide stability to inner catheter 14.
The movement of inner catheter 14 may be effected by any suitable mechanism for example, a proximally located ratchet and pawl mechanism as illustrated in FIG. 4. In this embodiment a locking mechanism 32 restricts the movement of the proximal end of inner catheter 14 by engaging with a plurality of nubs 34. Movement of mechanism 32 into a position, as illustrated by the dashed lines in
In addition, and as an alternative, mechanism 32 can work in conjunction with a return spring 39 which is depressed as inner catheter 14 is depressed. Accordingly, as mechanism 32 is released the force of spring 39 acts to return inner catheter 14 to its original position.
Optionally, inner catheter 14 may be provided with graduated markings 36. Markings 36 can indicate the relative position of opening 28 of inner catheter 14 with respect to opening 20 of outer catheter 12. For instance, a marking of zero would indicate that opening 28 and opening 20 are flush with each other. Other markings such as +1,+2,+3, or −1, −2, −3 would indicate the respective location of opening 28 with respect to 20.
In yet another embodiment markings 36 can indicate the flow output of sealant 22 depending on the position of opening 28. Depending on the size of catheters 12 and 14, markings 36 can be configured to indicate flow output of mixed sealant 22, such as millimeters per second or any other suitable indicator of flow output. In addition, markings 36 may also be configured to refer to the mixture ratio of component 24 with respect to component 26.
The movement of inner catheter 14 with respect to outer catheter 12 also allows a user to conveniently purge any clot of hardened sealant 22 from opening 20, as will now be further explained.
Turning now to
In yet another embodiment stabilizing ring 27 (
Stabilizing ring 27 allows component 26 to flow through area 18 unimpeded, however, stabilizing ring 27 is constructed in such a manner as to force clot 38 from opening 20 once stabilizing ring 27 has made contact with clot 38.
One such configuration is that of a spoked wheel (
Alternatively, ring or rings 27 is a disk having a plurality of smaller openings 35 (
Movement of stabilizing ring 27 is effected through the use of a trigger mechanism, such as a plunger or the equivalent thereof, positioned at the proximal end of applicator 10 which is conveniently accessed by the user's finger or thumb.
In yet another embodiment, ring or rings 27 are secured to inner catheter 14. Thus, as the user manipulates or moves inner catheter 14 ring 27 also moves.
In a still further embodiment, rings 27, or inner catheter 14 with rings 27 secured to it, are capable of being rotated as they are being depressed. Such rotation will enhance the dislodging of clot 38.
Other clot removal techniques such as those illustrated in
Alternatively, and as illustrated by the dashed lines in
Alternatively, catheters 12 and 14 may be constructed out of a flexible material capable of be manipulated at the proximal end of applicator 10 to effectively pinch off the supply of components 26 and 24. The compression of catheters 12 and 14 at the proximal end also causes small amounts of components 24 and 26 to be discharged. Such placement of a pinching mechanism or pinching capability at the proximal end of applicator 10 also provides for an ergonomic device.
Openings 28 and 20 may be equipped with a closing mechanism, such as a removable cover 31 (illustrated in
Referring now to
In this embodiment the end of catheter 114 is closed. Accordingly, mixed sealant 122 is applied to the required location through opening 120. Catheter 114 may also be positioned to apply sealant 122 as illustrated in
In the case where a clot 138 has blocked opening 120, catheter 114 may also be used as a plunger to remove clot 138 (as illustrated by the dashed lines in
In yet another embodiment, and as illustrated in
In addition and in order to aid in the clot expulsion as depicted in
Referring now to
Movement of inner catheter 14 is facilitated by the manipulation of an actuating mechanism 40 which is secured to inner catheter 14 via a clamping device 42. Such manipulation causes a corresponding movement of inner catheter 14, and may be effected by a manual control (not shown), for example a spring-loaded depressible button or trigger.
A flexible gasket 44 allows for movement of inner catheter 14 while providing a secure seal around catheters 14 and 12.
Outer catheter 12 is also connected to a connector 12a. Connector 12a supplies area 18 with sealant component 26. Connector 12a may also be flexible, however connector 12a may be constructed out of a more rigid material.
Referring now to
Referring now to
The embodiment of the invention shown in
Catheter sealant applicator 360 comprises a hollow outer sheath 364, an inner plug 366 which has an axial bore 368 and external channels 370, and a supply lumen 372 press-fitted into plug 366. As shown, four symmetrically disposed channels 370 are provided, but other numbers of channels 370 such as three, six or eight may be employed. The outer diameter of plug 366 is a close sliding fit within the inner diameter of sheath 364. The cross-sectional areas of channels 370 and bore 368 are selected to provide desired relative flow rates of sealant agents, which relative flow rates may be varied, or selected, by using plugs 366 of different configurations. Such diverse plugs 366 may be supplied each with a lumen 372, or may be interchangeably fittable to one or more lumens 372. Optionally, channels 370 on plug 366 can taper outwardly, in the fluid delivery direction, which is to say distally, to increase the channel area in the direction of flow and facilitate clearing and the removal of clots.
A further option is for channels 370 to have a helical configuration, as shown, simulating rifling, to impart spin to the fluid travel to enhance mixing of the sealant agents. In such case a still further option is for channels 370 to be twisted in opposed directions around plug 366, to impart countercurrent flows and further enhance mixing.
Preferably, the sealant catalyst, for example, in the case of a fibrinogen sealant, thrombin or other fibrinogen activator, is supplied through lumen 372 to bore 368 in plug 366, and fibrinogen or other polymerizable sealant agent, is supplied in the space between the outside of the lumen and the inside diameter 374 of sheath 364.
For application of sealant, the forward or distal face of plug 366 is slightly retracted behind the distal end of sheath 364 to allow mixing of the two agents to take place in a mixing volume disposed generally within the sheath 364. As with other embodiments described herein, significant mixing of the sealant components takes place before delivery of the sealant agents to, or contact of the sealant agents with, the target work surface.
Once a cycle of sealant application is complete, tip 362 can be cleared of any clot or other material, by advancing lumen 372, driving plug 366 forwardly inside sheath 364 and expelling the clot. If necessary, the clot can be freed from the face of plug 366, or loosened, by dispensing a small amount of sealant.
The invention provides a novel surgical method of applying sealant to unexposed or internal biological surfaces, e.g. human or animal anatomical surfaces, that are accessible to a catheter, for example, inner ear structures, the veins and arteries and organs such as the heart that are accessible via veins and arteries, the bladder, and so on. The method comprises use of a dual catheter such as described hereinabove, which is coupled to a sealant applicator to receive a flow of multiple sealant components from the applicator and to mix the sealant components at the distal end of the catheter, and insertion of the catheter into a body organ to advance the distal end of the catheter to a work site, operation of the sealant applicator to dispense sealant from the distal end of the dual catheter, and removal of the dual catheter from the body organ. After removal, the tip of the dual catheter will usually be cleared of any clog by operating the inner catheter as a plunger and ejecting the clog to waste. In an exceptional case, and with due care on the part of the surgeon or other operator, the inner catheter may be advanced while the dual catheter is inserted into a body organ, to free the dual or outer catheter, or clear and obstruction or, possibly, to manipulate the work surface.
While illustrative embodiments of the invention have been described above, it is, of course, understood that various modifications will be apparent to those of ordinary skill in the art. Many such modifications are contemplated as being within the spirit and scope of the invention.
This application claims the benefit of priority from provisional application Ser. No. 60/102,636 filed Oct. 1, 1998, and entitled “IMPROVED COMPONENT MIXING CATHETER,” the disclosure of which is hereby incorporated herein by reference thereto. This application discloses subject matter in the general field of commonly assigned copending U.S. patent applications Ser. Nos. 08/838,078 and 08/839,614, both filed Apr. 15, 1997, to patent application Ser. No. 08/946,364 filed Oct. 7, 1997, to patent application Ser. No. 09/037,160 filed Mar. 9, 1998 all naming Gordon H. Epstein as first inventor, and to U.S. patent application No. (unknown) filed May 21, 1998 naming Mitchell E. Levinson as first Inventor and entitled “SEALANT APPLICATOR AND METHOD EMPLOYING IMPULSE CLEARING”. The disclosures of the aformentioned United States patent applications, “the above applications” are hereby incorporated herein by reference thereto as is the disclosure of provisional application No. 60/102,636 from which the present application claims priority. Continuation status is not being claimed at this time with respect to the aforementioned non-provisional patent applications. This statement is made without prejudice to applicant's right to claim continuation status at any time during copendency of the present application with respect to another application.
Number | Name | Date | Kind |
---|---|---|---|
786985 | Nicholis | Apr 1905 | A |
1206126 | Mitsch | Nov 1916 | A |
1889425 | Sorensen | Nov 1932 | A |
2112160 | Johnson | Mar 1938 | A |
2158593 | Scrimgeour | May 1939 | A |
2576766 | Sokolik | Nov 1951 | A |
2812765 | Tofflemire | Nov 1957 | A |
3065749 | Brass | Nov 1962 | A |
3071402 | Lasto | Jan 1963 | A |
3144868 | Jascalevich | Aug 1964 | A |
3159312 | Sciver II | Dec 1964 | A |
3179107 | Clark | Apr 1965 | A |
3188056 | Trumbull | Jun 1965 | A |
3208145 | Turner | Sep 1965 | A |
3223083 | Cobey | Dec 1965 | A |
3469582 | Jackson | Sep 1969 | A |
3594980 | Diehl | Jul 1971 | A |
3625221 | Corbett | Dec 1971 | A |
3626928 | Barringer | Dec 1971 | A |
3645497 | Nyboer | Feb 1972 | A |
3672544 | Marand | Jun 1972 | A |
3737106 | Arnold et al. | Jun 1973 | A |
3767085 | Cannon | Oct 1973 | A |
3771522 | Waysilk et al. | Nov 1973 | A |
3790080 | Babington | Feb 1974 | A |
3828980 | Creighton | Aug 1974 | A |
3865193 | Hall | Feb 1975 | A |
3918935 | Livingston | Nov 1975 | A |
3949748 | Malmin | Apr 1976 | A |
3991143 | Carter | Nov 1976 | A |
4036210 | Campbell et al. | Jul 1977 | A |
4037665 | Hopper | Jul 1977 | A |
4040420 | Speer | Aug 1977 | A |
4043042 | Perfect | Aug 1977 | A |
4067479 | Moline | Jan 1978 | A |
4109653 | Kozam et al. | Aug 1978 | A |
4143658 | Rambosek et al. | Mar 1979 | A |
4170232 | Khoury | Oct 1979 | A |
4191480 | Hiorth | Mar 1980 | A |
4193406 | Jinotti | Mar 1980 | A |
4198958 | Utsugi | Apr 1980 | A |
4223676 | Wuchinich et al. | Sep 1980 | A |
4231521 | Hermine | Nov 1980 | A |
4236674 | Dixon | Dec 1980 | A |
4266545 | Moss | May 1981 | A |
4270525 | Furihata | Jun 1981 | A |
4294251 | Greenwald et al. | Oct 1981 | A |
4298598 | Schwarz et al. | Nov 1981 | A |
4299221 | Phillips et al. | Nov 1981 | A |
4325913 | Wardlaw | Apr 1982 | A |
4356823 | Jackson | Nov 1982 | A |
4359049 | Redl et al. | Nov 1982 | A |
4362567 | Schwarz et al. | Dec 1982 | A |
4377572 | Schwarz et al. | Mar 1983 | A |
4396417 | Lissant | Aug 1983 | A |
4397640 | Haug et al. | Aug 1983 | A |
4401271 | Hansen | Aug 1983 | A |
4401272 | Merton et al. | Aug 1983 | A |
4414976 | Schwarz et al. | Nov 1983 | A |
4427650 | Stroetmann | Jan 1984 | A |
4445517 | Feild | May 1984 | A |
4487600 | Brownlie et al. | Dec 1984 | A |
4504266 | Harle | Mar 1985 | A |
4516442 | Davis | May 1985 | A |
4519385 | Atkinson et al. | May 1985 | A |
4573979 | Blake | Mar 1986 | A |
4601697 | Mammolenti et al. | Jul 1986 | A |
4617013 | Betz | Oct 1986 | A |
4629455 | Kanno | Dec 1986 | A |
4631055 | Redl et al. | Dec 1986 | A |
4670009 | Bullock | Jun 1987 | A |
4680026 | Weightman et al. | Jul 1987 | A |
4690306 | Staheli | Sep 1987 | A |
4696669 | Menhusen | Sep 1987 | A |
4699138 | Behrstock | Oct 1987 | A |
4708717 | Deane et al. | Nov 1987 | A |
4728578 | Higgins et al. | Mar 1988 | A |
4735616 | Eibl et al. | Apr 1988 | A |
4735619 | Sperry et al. | Apr 1988 | A |
4743229 | Chu | May 1988 | A |
4759349 | Betz et al. | Jul 1988 | A |
4776840 | Freitas et al. | Oct 1988 | A |
4784637 | Ryder et al. | Nov 1988 | A |
4842581 | Davis | Jun 1989 | A |
4857047 | Amoils | Aug 1989 | A |
4874368 | Miller et al. | Oct 1989 | A |
4891044 | Mitchell | Jan 1990 | A |
4902281 | Avoy | Feb 1990 | A |
4904238 | Williams | Feb 1990 | A |
4925447 | Rosenblatt | May 1990 | A |
4928884 | Smith | May 1990 | A |
4935006 | Hasson | Jun 1990 | A |
4941872 | Felix | Jul 1990 | A |
4946439 | Eggers | Aug 1990 | A |
4969669 | Sauer | Nov 1990 | A |
4978336 | Capozzi et al. | Dec 1990 | A |
4979942 | Wolf et al. | Dec 1990 | A |
4981473 | Rosenblatt | Jan 1991 | A |
5024615 | Buchel | Jun 1991 | A |
5024654 | Tyler | Jun 1991 | A |
RE33642 | Lester | Jul 1991 | E |
5029580 | Radford et al. | Jul 1991 | A |
5030201 | Palestrant | Jul 1991 | A |
5030202 | Harris | Jul 1991 | A |
5030215 | Morse et al. | Jul 1991 | A |
5045055 | Gonser et al. | Sep 1991 | A |
5049135 | Davis | Sep 1991 | A |
5061180 | Wiele | Oct 1991 | A |
5104375 | Wolf | Apr 1992 | A |
5116315 | Capozzi et al. | May 1992 | A |
5120305 | Boehringer et al. | Jun 1992 | A |
5147323 | Haber | Sep 1992 | A |
5163433 | Kagawa et al. | Nov 1992 | A |
5186714 | Boudreault et al. | Feb 1993 | A |
5199949 | Haber | Apr 1993 | A |
5217441 | Shichman | Jun 1993 | A |
5217465 | Steppe | Jun 1993 | A |
5226877 | Epstein | Jul 1993 | A |
5240146 | Smedley | Aug 1993 | A |
5246455 | Shikani | Sep 1993 | A |
5253785 | Haber | Oct 1993 | A |
5271527 | Haber et al. | Dec 1993 | A |
5286258 | Haber et al. | Feb 1994 | A |
5290552 | Sierra et al. | Mar 1994 | A |
5295956 | Bales et al. | Mar 1994 | A |
5300022 | Klapper et al. | Apr 1994 | A |
5304165 | Haber et al. | Apr 1994 | A |
5314412 | Rex | May 1994 | A |
5318782 | Weis-Fogh | Jun 1994 | A |
5328459 | Laghi | Jul 1994 | A |
5348542 | Ellis | Sep 1994 | A |
5368560 | Rambo et al. | Nov 1994 | A |
5368563 | Lonneman et al. | Nov 1994 | A |
5376079 | Holm | Dec 1994 | A |
5395326 | Haber et al. | Mar 1995 | A |
5405607 | Epstein | Apr 1995 | A |
5419769 | Devlin | May 1995 | A |
5423752 | Haber | Jun 1995 | A |
5433705 | Giebel et al. | Jul 1995 | A |
5443454 | Tanabe et al. | Aug 1995 | A |
5447494 | Dorsey, III | Sep 1995 | A |
5474540 | Miller et al. | Dec 1995 | A |
5476450 | Ruggio | Dec 1995 | A |
5477987 | Keller | Dec 1995 | A |
5520658 | Holm | May 1996 | A |
5520685 | Wojciechowicz | May 1996 | A |
5571081 | Adhoute | Nov 1996 | A |
5582596 | Fukunaga et al. | Dec 1996 | A |
5584815 | Pawelka | Dec 1996 | A |
5585007 | Antanavich et al. | Dec 1996 | A |
5603700 | Daneshvar | Feb 1997 | A |
5605255 | Reidel et al. | Feb 1997 | A |
5605541 | Holm | Feb 1997 | A |
5612050 | Rowe et al. | Mar 1997 | A |
5626562 | Castro | May 1997 | A |
5643206 | Fischer | Jul 1997 | A |
5648265 | Epstein | Jul 1997 | A |
5656035 | Avoy | Aug 1997 | A |
5665067 | Linder et al. | Sep 1997 | A |
5674394 | Whitmore | Oct 1997 | A |
5695472 | Wyrick | Dec 1997 | A |
5749968 | Melanson et al. | May 1998 | A |
5759169 | Marx | Jun 1998 | A |
5759171 | Coelho et al. | Jun 1998 | A |
5779108 | Barriac et al. | Jul 1998 | A |
5779721 | Nash | Jul 1998 | A |
5810885 | Zinger | Sep 1998 | A |
5814022 | Antanavich | Sep 1998 | A |
5814066 | Spotnitz | Sep 1998 | A |
5833652 | Preissman et al. | Nov 1998 | A |
5879340 | Epstein | Mar 1999 | A |
5902264 | Toso et al. | May 1999 | A |
5964261 | Neuenfeldt et al. | Oct 1999 | A |
5975367 | Coelho et al. | Nov 1999 | A |
5976102 | Epstein | Nov 1999 | A |
5984889 | Christ | Nov 1999 | A |
5989215 | Delmotte et al. | Nov 1999 | A |
6007515 | Epstein | Dec 1999 | A |
6036103 | Benest | Mar 2000 | A |
6063055 | Epstein et al. | May 2000 | A |
6068203 | DeYoung et al. | May 2000 | A |
6113571 | Zinger et al. | Sep 2000 | A |
6132396 | Antanavich et al. | Oct 2000 | A |
6139520 | McCrory et al. | Oct 2000 | A |
6161730 | Heusser et al. | Dec 2000 | A |
6183941 | Hayes | Feb 2001 | B1 |
6206905 | Holm et al. | Mar 2001 | B1 |
6234994 | Zinger | May 2001 | B1 |
6328229 | Duronio et al. | Dec 2001 | B1 |
6331172 | Epstein et al. | Dec 2001 | B1 |
6394975 | Epstein | May 2002 | B1 |
6461325 | Delmotte et al. | Oct 2002 | B1 |
Number | Date | Country |
---|---|---|
26 05 005 | Feb 1976 | DE |
8133489 | May 1982 | DE |
196 36 622 | Jun 1998 | DE |
0 037 393 | Apr 1981 | EP |
0 156 098 | Dec 1984 | EP |
0 302 411 | Jul 1988 | EP |
0 424 068 | Oct 1990 | EP |
0538 174 | Sep 1992 | EP |
0 669 100 | Feb 1995 | EP |
0 800 361 | Dec 1995 | EP |
0738 498 | Apr 1996 | EP |
0 738 498 | Oct 1996 | EP |
0858 775 | Feb 1998 | EP |
WO 8704913 | Aug 1987 | WO |
WO 9531137 | Nov 1995 | WO |
WO 9639212 | Dec 1996 | WO |
WO 9728834 | Aug 1997 | WO |
WO 9810704 | Mar 1998 | WO |
WO 9917833 | Apr 1999 | WO |
WO 9959670 | Nov 1999 | WO |
Number | Date | Country | |
---|---|---|---|
60102636 | Oct 1998 | US |